About EPOK Therapeutics
EPOK Therapeutics is a company based in Toronto (Canada) founded in 2023. It operates as a B2B. EPOK Therapeutics offers products and services including KLOT-1123 and EPRA-0322. EPOK Therapeutics operates in a competitive market with competitors including Ardelyx, DermBiont, Inozyme Pharma, Kriya Therapeutics and Vedanta Biosciences, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Epok Therapeutics Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EPOK Therapeutics
EPOK Therapeutics offers a comprehensive portfolio of products and services, including KLOT-1123 and EPRA-0322. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Selectively targets FGF23 for treating phosphate wasting disorders in CKD.
Provides low-dose treatment for chronic anemia with enhanced safety.
Funding Insights of EPOK Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by EPOK Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EPOK Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Epok Therapeutics Comparisons
Competitors of EPOK Therapeutics
EPOK Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ardelyx, DermBiont, Inozyme Pharma, Kriya Therapeutics and Vedanta Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Microbial therapeutics for skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of treatments for rare and debilitating metabolic diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Therapeutics for infectious and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Synthetic biology platform is utilized to develop small-molecule therapeutics.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about EPOK Therapeutics
When was EPOK Therapeutics founded?
EPOK Therapeutics was founded in 2023.
Where is EPOK Therapeutics located?
EPOK Therapeutics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
What does EPOK Therapeutics do?
EPOK Therapeutics, founded in 2023, specializes in advancing biologic therapies for metabolic diseases through engineered agonist and antagonist antibodies. They aim to reduce off-target activity and enhance safety for conditions like chronic kidney disease, anemia, and phosphate imbalances. The company leverages expertise in antibody engineering and preclinical research, operating from Toronto, Canada, with a subsidiary in Hayward, USA, and collaborates with partners in healthcare.
Who are the top competitors of EPOK Therapeutics?
EPOK Therapeutics's top competitors include Ardelyx, Vedanta Biosciences and Ilya Pharma.
What products or services does EPOK Therapeutics offer?
EPOK Therapeutics offers KLOT-1123 and EPRA-0322.